Log in to search using one of your social media accounts:

 

Mylan Launches First AP-rated Generic Avelox(R) Injection
HERTFORDSHIRE, England and PITTSBURGH, Oct. 5, 2017 -- (Healthcare Sales & Marketing Network) -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Moxifloxacin Hydrochloride in 0.8% Sodium Chloride Injection, 400 mg/250 mL (1.6 mg/mL) in 2... Biopharmaceuticals, Product Launch Mylan, Moxifloxacin, Avelox, fluoroquinolone, antibacterial (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 5, 2017 Category: Pharmaceuticals Source Type: news

Tuberculosis drug may work better than others in its class
(PLOS) Treatment of tuberculosis involves a combination of several drugs, sometimes including drugs from a class known as fluoroquinolones. Using computer simulations, scientists have shown that the fluoroquinolone known as moxifloxacin may be superior to two other commonly used fluoroquinolones, according to a new paper in PLOS Computational Biology. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - August 17, 2017 Category: Infectious Diseases Source Type: news

FDA Warns About Triamcinolone and Moxifloxacin Combo for Eye FDA Warns About Triamcinolone and Moxifloxacin Combo for Eye
The FDA issued a safety alert after serious adverse events were reported in at least 43 patients who received a compounded triamcinolone and moxifloxacin product by intravitreal injection.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 28, 2017 Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news

Paratek shares soar as antibiotic passes late-stage hurdle
Shares of Paratek Pharmaceuticals jumped in after-hours trading Monday after the Boston-based biotech said that its lead antibiotic drug had performed well in a Phase 3 study involving patients with hospital-acquired pneumonia. The news comes a week after reporting positive data from a late-stage trial of an acne treatment. Paratek (Nasdaq: PRTK) said the 774-patient study had showed that omadacycline was nearly as effective as another common antibiotic, moxifloxacin, in helping patients reduce… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - April 4, 2017 Category: Health Management Authors: Max Stendahl Source Type: news

Paratek shares soar as antibiotic passes late-stage hurdle
Shares of Paratek Pharmaceuticals jumped in after-hours trading Monday after the Boston-based biotech said that its lead antibiotic drug had performed well in a Phase 3 study involving patients with hospital-acquired pneumonia. The news comes a week after reporting positive data from a late-stage trial of an acne treatment. Paratek (Nasdaq: PRTK) said the 774-patient study had showed that omadacycline was nearly as effective as another common antibiotic, moxifloxacin, in helping patients reduce… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 4, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

Avelox (Moxifloxacin HCL) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 8, 2016 Category: Drugs & Pharmacology Source Type: news

Yet Another Warning On Fluoroquinolone Antibiotic Side Effects
Rare but significant and debilitating side effects - tendon rupture, peripheral neuropathy - can occur with fluoroquinolone antibiotics like Avelox or Cipro. The FDA is now warning that some of these side effects can occur together and that use of these drugs should be restricted for most uncomplicated infections. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - August 1, 2016 Category: Pharmaceuticals Authors: David Kroll Source Type: news

FDA Calls for More Restrictions on Fluoroquinolone Use (FREE)
By Kristin J. Kelley Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH The risks for "disabling and potentially permanent" side effects associated with systemic fluoroquinolone antibacterials (e.g., ciprofloxacin, moxifloxacin) generally outweigh the benefits in patients with … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 15, 2016 Category: Primary Care Source Type: news

Novel Antibiotic Shows Promise for Community-Acquired Pneumonia (FREE)
By Amy Orciari Herman Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH Oral solithromycin is noninferior to moxifloxacin for the treatment of community-acquired bacterial pneumonia, according to an industry-funded, phase 3 trial published … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 8, 2016 Category: Primary Care Source Type: news

Advantages Claimed for Dropless Cataract SurgeryAdvantages Claimed for Dropless Cataract Surgery
Use of a combined triamcinolone/moxifloxacin compound improves therapeutic compliance, enhances prophylaxis against infection, and costs less than conventional eyedrops. Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 21, 2015 Category: Consumer Health News Tags: Ophthalmology Article Source Type: news

Nanoparticle delivery maximizes drug defense against bioterrorism agent
Scientists from the California NanoSystems Institute at UCLA have developed a nanoparticle delivery system for the antibiotic moxifloxacin that vastly improves the drug’s effectiveness against pneumonic tularemia, a type of pneumonia caused by inhalation of the bacterium Francisella tularensis. The study, which appears in the journal ACS Nano, shows how the nanoparticle system targets the precise cells infected by the bacteria and maximizes the amount of drug delivered to those cells. Jeffrey Zink, distinguished professor of chemistry and biochemistry and a senior author on the study, developed the mesoporous si...
Source: UCLA Newsroom: Health Sciences - November 6, 2015 Category: Universities & Medical Training Source Type: news

Avelox Approved for Plague
Title: Avelox Approved for PlagueCategory: Health NewsCreated: 5/8/2015 12:00:00 AMLast Editorial Review: 5/11/2015 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - May 11, 2015 Category: Drugs & Pharmacology Source Type: news

Moxifloxacin Approved for Treating Plague (FREE)
By Kristin J. Kelley Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH The antibiotic moxifloxacin (Avelox) has been approved for the prevention and treatment of pneumonic plague … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 11, 2015 Category: Primary Care Source Type: news

FDA Expands Indication of Moxifloxacin (Avelox) for PlagueFDA Expands Indication of Moxifloxacin (Avelox) for Plague
The antibiotic comes with a boxed warning about serious adverse events, but given the deadly nature of plague, "the benefit...outweighs these potential risks," the agency said. FDA Approvals (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - May 9, 2015 Category: Emergency Medicine Tags: Infectious Diseases News Alert Source Type: news

FDA approves additional antibacterial treatment for plague
The U.S. Food and Drug Administration today approved Avelox (moxifloxacin) to treat patients with plague, a rare and potentially fatal bacterial infection. The agency approval for plague includes use of the drug for the treatment of pneumonic plague (infection of the lungs), and septicemic plague (infection of the blood). Avelox is also approved for prevention of plague in adult patients. (Source: Food and Drug Administration)
Source: Food and Drug Administration - May 8, 2015 Category: American Health Source Type: news

Evidence Linking Some Fluoroquinolones to Uveitis GrowsEvidence Linking Some Fluoroquinolones to Uveitis Grows
Moxifloxacin or ciprofloxacin appear to increase the risk for uveitis; levofloxacin less so. Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - October 7, 2014 Category: Infectious Diseases Tags: Internal Medicine News Source Type: news

Moxifloxacin Struggles Against Current TB Drugs: REMox TrialMoxifloxacin Struggles Against Current TB Drugs: REMox Trial
Although a shorter, moxifloxacin-containing regimen did not measure up to standard tuberculosis therapy, the drug shows promise, experts say. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 7, 2014 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

4-Drug Combo May Reduce TB Therapy Time
BOSTON (MedPage Today) -- Substituting rifapentine (Priftin) and moxifloxacin (Avelox) for two of four standard drugs may reduce the time necessary to treat patients infected with tuberculosis, researchers reported here. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - March 10, 2014 Category: Primary Care Source Type: news

Dr Reddy's launches antibiotic drug in US market
According to IMS Health, Avelox (moxifloxacin HCl) tablets had a sales figure of approximately USD 195 millions in 2013, the release said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 5, 2014 Category: Pharmaceuticals Source Type: news

Treatment of Infections Due to Resistant Staphylococcus aureus
This chapter reviews data on the treatment of infections caused by drug-resistant Staphylococcus aureus, particularly methicillin-resistant S. aureus (MRSA). This review covers findings reported in the English language medical literature up to January of 2013. Despite the emergence of resistant and multidrug-resistant S. aureus, we have seven effective drugs in clinical use for which little resistance has been observed: vancomycin, quinupristin–dalfopristin, linezolid, tigecycline, telavancin, ceftaroline, and daptomycin. However, vancomycin is less effective for infections with MRSA isolates that have a higher MIC w...
Source: Springer protocols feed by Microbiology - October 6, 2013 Category: Microbiology Source Type: news

Fluoroquinolones Up Risk for Severe Dysglycemia in DiabetesFluoroquinolones Up Risk for Severe Dysglycemia in Diabetes
Use of fluoroquinolones, in particular moxifloxacin, appears to increase the risk of severe blood glucose swings in patients with diabetes compared with the use of other classes of antibiotic. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 15, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Certain Antibiotics Tied to Blood Sugar Swings in Diabetics
Drugs such as Cipro, Avelox were most implicated, but experts say other factors may be at play Source: HealthDay Related MedlinePlus Pages: Antibiotics, Blood Sugar, Diabetes (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - August 15, 2013 Category: Consumer Health News Source Type: news

Study examines risk of severe blood sugar swings among diabetics taking fluoroquinolones
(Infectious Diseases Society of America) Diabetic patients taking oral fluoroquinolones, a frequently prescribed class of antibiotics, were found to have a higher risk of severe blood sugar-related problems than diabetic patients taking other kinds of antibiotics, according to a recent study from Taiwan published in Clinical Infectious Diseases. The increased risk was low, but clinicians should consider the higher risk when treating diabetic patients with fluoroquinolones, especially moxifloxacin, and prescribe them cautiously, the study's authors concluded. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 15, 2013 Category: Global & Universal Source Type: news

Risk Of Kidney Disease Doubled With Use Of Fluoroquinolone Antibiotics
The risk of acute kidney disease is doubled for people taking oral fluoroquinolone antibiotics, according to a study of published in CMAJ (Canadian Medical Association Journal). Fluoroquinolones, including ciprofloxacin, levofloxacin and moxifloxacin, are common broad-spectrum antibiotics most often used to treat respiratory and urogenital infections. Case reports have indicated acute kidney injury with use, and prescription labels carry a warning of kidney failure. However, when oral fluoroquinolones are prescribed in clinical practice, kidney injury is usually not considered... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 3, 2013 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news

Moxifloxacin versus ciprofloxacin plus co-amoxiclav for fever in low-risk neutropoenic patients with cancer
Source: Journal of Clinical Oncology Area: News According to the results of a double-blind RCT, monotherapy with once daily oral moxifloxacin is associated with similar efficacy to ciprofloxacin plus co-amoxiclav combination therapy in the treatment of fever in adults with cancer and neutropoenia who are deemed to be at low-risk of complications.   The authors note that prompt empirical antibiotic therapy for fever in patients with neutropenia has become the standard of care; current guidelines recommend oral ciprofloxacin plus co-amoxiclav as the standard regimen for those who are low-risk. The purpose of the cu...
Source: NeLM - News - January 29, 2013 Category: Drugs & Pharmacology Source Type: news